Literature DB >> 3470546

Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38.

E G Mayhew, M H Goldrosen, J Vaage, Y M Rustum.   

Abstract

The effects of doxorubicin (DOX) and DOX entrapped in standardized liposomes [mean diameter, 0.15 micron; (DOX-Lip)] on the survival of mice bearing liver metastases of mouse colon carcinoma CT38LD (C57BL/6J mice) or CT26 (BALB/c mice) were investigated. In vitro cultured CT38LD cells were more sensitive to DOX than CT26. In vivo DOX and DOX-Lip, administered iv 10 mg/kg weekly to a maximum of five injections, increased the life-spans of mice bearing CT38LD liver metastases 32% (P less than .05) and 64% (P less than .05), respectively. DOX-Lip was more effective than DOX in prolonging survival (P less than .05). Free DOX did not significantly increase the life-spans of mice bearing CT26 liver metastases (P greater than .5), whereas DOX-Lip increased the life-spans 35% (P less than .05). The results suggest that liposomal delivery of agents to the liver can enhance therapeutic activity and could be used as an arm of protocols for adjuvant therapy of liver metastases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3470546

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

1.  Liposomal formulation and antitumor activity of 14-O-palmitoyl-hydroxyrubicin.

Authors:  R Perez-Soler; W Priebe
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

Authors:  D Papahadjopoulos; T M Allen; A Gabizon; E Mayhew; K Matthay; S K Huang; K D Lee; M C Woodle; D D Lasic; C Redemann
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

3.  Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.

Authors:  R A Schwendener; H H Fiebig; M R Berger; D P Berger
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas.

Authors:  Cameron C Lee; Elizabeth R Gillies; Megan E Fox; Steven J Guillaudeu; Jean M J Fréchet; Edward E Dy; Francis C Szoka
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

5.  Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.

Authors:  H M Yang; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

6.  Effect of combined administration of a synthetic low-toxicity lipid A derivative, DT-5461a, and indomethacin in various experimental tumor models of colon 26 carcinoma in mice.

Authors:  T Jimbo; T Akimoto; A Tohgo
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

7.  Organ distribution and antitumor activity of free and liposomal doxorubicin injected into the hepatic artery.

Authors:  Y Zou; I Horikoshi; T Kasagi; X Gu; R Perez-Soler
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  A phase II trial of doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma.

Authors:  G K Schwartz; E S Casper
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

9.  Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

Authors:  P Guaglianone; K Chan; E DelaFlor-Weiss; R Hanisch; S Jeffers; D Sharma; F Muggia
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

10.  Preparation, characterization and application of star-shaped PCL/PEG micelles for the delivery of doxorubicin in the treatment of colon cancer.

Authors:  Xiang Gao; BiLan Wang; XiaWei Wei; Wang Rao; Fang Ai; Fen Zhao; Ke Men; Bowen Yang; Xingyu Liu; Meijuan Huang; Maling Gou; ZhiYong Qian; Ning Huang; Yuquan Wei
Journal:  Int J Nanomedicine       Date:  2013-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.